Dewpoint congratulates our scientific founder, Tony Hyman, for his election to the German Academy of Sciences Leopoldina. This prestigious award […]

A Nature review of condensate focused start-ups has described Dewpoint as the “field’s frontrunner’. The article has profiled three condensate […]

The announcement of Dewpoint Therapeutics successful $77 million Series B raise has received significant attention in from both Industry and […]

Dewpoint congratulates its co-founder, Tony Hyman, who was this week elected to the National Academy of Sciences in honor of his […]

Dewpoint congratulates its co-founder Tony Hyman, for receiving the NOMIS Foundation’s Distinguished Scientist and Scholar Award.  The award recognises outstanding contributions […]

Dewpoint Therapeutics co-founder Anthony Hyman will share the 2020 Wiley Prize in Biomedical Sciences for his foundational work on biomolecular […]

The announcement of Dewpoint Therapeutics $100M partnership Bayer to research new treatments for cardiovascular and gynecological diseases has received significant […]

Dewpoint congratulates our scientific founder, Richard Young, on being named to the National Academy of Medicine.

BERLIN / BOSTON, September 23, 2019 –  Rounding out a year of tremendous growth on two continents, Dewpoint Therapeutics, the biomolecular condensates company, has […]

The announcement of the launch of Dewpoint Therapeutics, with $60 Million Series A funding has received significant attention from media […]